COMP <GO>
ZBH vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Zimmer Biomet Holdings Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ZBH 5
— LLY 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $94.52 (-3.03%) • MKT CAP: $18.59B
balance-sheet
2.42
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZBH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZBH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.70% | 83.64% | -13.94 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 32.36% | -27.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.3x | 36.4x | -17.12 | ZBH | /valuation <GO> |
| Free Cash Flow Yield | 7.92% | 2.30% | +5.62 | ZBH | /fcf-yield <GO> |
| Operating Margin | 13.30% | 40.21% | -26.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | 8.60% | 31.90% | -23.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 7.20% | 45.51% | -38.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.02% | 0.49% | +0.53 | ZBH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.42 | 9.29 | -6.87 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.77% | +0.23 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 77.9 | -28.11 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.51 | +0.51 | ZBH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.6x | 26.3x | -1.65 | ZBH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.59B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZBH REV | LLY REV | ZBH GROSS % | LLY GROSS % | ZBH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.23B | $65.18B | 69.7% | 83.0% | $1.47B | $16.81B |
| FY 2024 | $7.68B | $45.04B | 71.5% | 81.3% | $1.30B | $8.82B |
| FY 2023 | $7.39B | $34.12B | 44.0% | 79.3% | $1.25B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZBH // BETA 1.02
LLY // BETA 0.51